(Q37798254)

23 August 2017

title

Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas (English)

1 reference

23 August 2017

0 references

Marc C Chamberlain

1

1 reference

23 August 2017

publication date

1 October 2010

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

23 August 2017

published in

1 reference

23 August 2017

volume

10

1 reference

23 August 2017

issue

10

1 reference

23 August 2017

page(s)

1537-1544

1 reference

The 2007 WHO classification of tumours of the central nervous system

23 August 2017

cites work

1 reference

Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial

21 January 2018

1 reference

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

21 January 2018

1 reference

Clinical impact of adjuvant chemotherapy in glioblastoma multiforme : a meta-analysis

21 January 2018

1 reference

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma

21 January 2018

1 reference

Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

21 January 2018

1 reference

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

21 January 2018

1 reference

Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.

21 January 2018

1 reference

Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas.

21 January 2018

1 reference

Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.

21 January 2018

1 reference

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

21 January 2018

1 reference

Clinical relevance of MGMT in the treatment of cancer

21 January 2018

1 reference

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

Targeted modulation of MGMT: clinical implications

21 January 2018

1 reference

Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity

21 January 2018

1 reference

Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia

21 January 2018

1 reference

21 January 2018

1 reference

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

21 January 2018

1 reference

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas

21 January 2018

1 reference

Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.

21 January 2018

1 reference

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme

21 January 2018

1 reference

Mechanisms of disease: temozolomide and glioblastoma--look to the future

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERN.10.32

1 reference

23 August 2017

1 reference